Provided is a process for production of fucoxanthin and/or polysaccharides from microalgae and the use of purified fucoxanthin thereof in pharmaceutical, cosmetic, nutraceutical and food compositions.

The present disclosure describes a topical composition, and related masks comprising the compositions disclosed herein, for applying to skin for treating acne or skin rejuvenation, the compositions comprising a light activated enzymatic extract; adaptogenic Baobab (Adansonia digitata) seed extract; adaptogenic wild indigo (Tephrosia purpurea) extract; pre- and/or pro-biotic extracts; and a carrier. The mask may be embodied in, or comprise, a hydrogel matrix or a biocellulose material or other fibrous material.

Mutant photosynthetic organisms having reduced chlorophyll and increased photosynthetic efficiency are provided. The mutant strains have mutated or attenuated: chloroplastic SRP54 gene and SGI1 gene; chloroplastic SRP54 gene and SGI2 gene; chloroplastic SRP54 gene, SGI1, and SGI2 genes are disclosed. The mutant photosynthetic organisms exhibit increased productivity with respect to wild-type strains. Also provided are mutant photosynthetic organisms having mutated or attenuated cytosolic SRP54 genes. Provided herein are methods of producing biomass and other products such as lipids using strains having mutations in an SRP54 gene, SGI1, SGI2 genes, a combination of SGI1/SRP54, and a combination of SGI2 and SRP54 genes. Also included are constructs and methods for attenuating or disrupting SRP54, SGI1, and SGI2 genes.

Mutant photosynthetic organisms having reduced chlorophyll and increased photosynthetic efficiency are provided. The mutant strains have mutated or attenuated: chloroplastic SRP54 gene and SGI1 gene; chloroplastic SRP54 gene and SGI2 gene; chloroplastic SRP54 gene, SGI1, and SGI2 genes are disclosed. The mutant photosynthetic organisms exhibit increased productivity with respect to wild-type strains. Also provided are mutant photosynthetic organisms having mutated or attenuated cytosolic SRP54 genes. Provided herein are methods of producing biomass and other products such as lipids using strains having mutations in an SRP54 gene, SGI1, SGI2 genes, a combination of SGI1/SRP54, and a combination of SGI2 and SRP54 genes. Also included are constructs and methods for attenuating or disrupting SRP54, SGI1, and SGI2 genes.

The use of a preparation for nutrition-based support of the body's own wound healing processes at the local and systemic level by oral intake of the preparation, which contains per gram as a basic preparation the following mixture of vitamins and nutrients: a. 330-385 μg of vitamin B1, b. 420-490 μg of vitamin B2, c. 4.8-5.6 mg of vitamin B3, d. 1.8-2.1 mg of vitamin B5, e. 420-490 μg of vitamin B6, f. 15-18 μg of vitamin H, g. 80-390 μg of vitamin B9, h. 1.0-4.9 μg of vitamin B12, i. 32-156 mg of vitamin C, j. 150-731 mg of magnesium, k. 4-20 mg of zinc and l. 3-200 mg of tryptophan.

The use of a preparation for nutrition-based support of the body's own wound healing processes at the local and systemic level by oral intake of the preparation, which contains per gram as a basic preparation the following mixture of vitamins and nutrients: a. 330-385 μg of vitamin B1, b. 420-490 μg of vitamin B2, c. 4.8-5.6 mg of vitamin B3, d. 1.8-2.1 mg of vitamin B5, e. 420-490 μg of vitamin B6, f. 15-18 μg of vitamin H, g. 80-390 μg of vitamin B9, h. 1.0-4.9 μg of vitamin B12, i. 32-156 mg of vitamin C, j. 150-731 mg of magnesium, k. 4-20 mg of zinc and l. 3-200 mg of tryptophan.

A medicament for use in treating hypertension. The medicament is a glycoprotein, a mixture of polysaccharide and protein, a polypeptide or a protein.

A medicament for use in treating hypertension. The medicament is a glycoprotein, a mixture of polysaccharide and protein, a polypeptide or a protein.

A medicament for use in treating hypertension. The medicament is a glycoprotein, a mixture of polysaccharide and protein, a polypeptide or a protein.

There is a composition for maximizing NAD enzyme's health benefits. The composition includes a nucleoside; the nucleoside is adenosine. The nucleoside is a phosphate derivative; wherein the composition includes 1 to 5 percent weight of adenosine. The composition includes a vitamin B3; wherein the vitamin B3 is in the form of niacin, niacinamide, nicotinic acid or nicotinamide. The composition includes 0.1 to 10 percent weight of the Vitamin B3. The composition includes a nicotinamide mononucleotide. The composition includes a stilbene derivative; wherein the composition includes 0.1 to 5 percent weight stilbene derivative.